Allena Pharmaceuticals
David J. Clark, M.D. has served as the Chief Medical Officer since November 2020. He has over 20 years of global industry experience in biopharmaceutical companies based in the United States and Europe.
Before joining Allena, Dr. Clark served as the Chief Medical Officer of Aldeyra Therapeutics, a publicly-traded biotechnology company developing medicines for immune-mediated ocular and systemic diseases from 2016 to 2020, and as the Chief Medical Officer of Wilson Therapeutics, a privately-held biotechnology company developing novel pharmaceuticals to treat Wilson Disease, a rare autosomal recessive disorder of copper metabolism. He served in similar roles from 2009, initially as Chief Medical Officer at NormOxys Inc. and then at TransTech Pharma, LLC. Previously, Dr. Clark held clinical leadership roles of increasing responsibility at Pfizer Inc. GlaxoSmithKline plc and SmithKline Beecham from 1997 to 2009.
Dr. Clark received his medical degree from the University of Edinburgh, trained in internal medicine, and conducted respiratory medicine academic research in the U.K. before moving into pharmaceutical industry research.
This person is not in any offices
Allena Pharmaceuticals
Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease.